August 28, 2018 – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, was proud to sponsor and participate in the 2018 Bert Blain Memorial Heart Walk in Janesville, WI. Held on August 26th, the walk supported the American Heart Association’s mission to reduce disability and death caused by cardiovascular disease and stroke.
This is the second year SHINE has participated in the local Heart Walk, which is one of the largest in the nation and brings together hundreds in the Janesville community to improve heart health in Wisconsin. In 2017, SHINE raised more than double its fundraising goal, and this year is proud to have exceeded its goal for the second year in a row, raising $4,333.
“Once again, our SHINE employees, friends and family members stepped up to support the Heart Walk. As a start-up company and member of this community, SHINE is extremely proud to support this longtime Janesville event,” said Cheryl Peterson, Community and Employee Engagement Manager at SHINE. Ms. Peterson lead the SHINE team, 21 of whom participated in the walk. SHINE’s team currently ranks fourth in the Top Companies and Top Teams categories for fundraising.
SHINE understands that its business is enriched by the community it calls home and that everyone has a responsibility to give back. SHINE prioritizes opportunities for community engagement that complement its mission, including those that help eradicate heart disease and cancer.
This year marked the 26thanniversary of the Bert Blain Memorial Heart Walk. As of today, the Heart Walk has raised over $196,000, and final donations are still being collected.
Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including Mo‑99.
About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals.